Lamivudine
- Product NDC
- 65862-553
- 11-digit product format
- 658620553
- Labeler code
- 65862
- Product ID
- 65862-553_199cd88b-1136-4ac0-a58d-81ea700ce718
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Aurobindo Pharma Limited
- Application
- ANDA202032
- Marketing category
- ANDA
- Marketing start
- 2011-11-17
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE
- Active strength
- 300 mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2020-12-31
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 65862-553-10 | 65862055310 | 3 BLISTER PACK in 1 CARTON (65862-553-10) > 10 TABLET, FILM COATED in 1 BLISTER PACK | 3 blister pack | 2011-11-17 | 0000-00-00 | No | No | Current |
| 65862-553-30 | 65862055330 | 30 TABLET, FILM COATED in 1 BOTTLE (65862-553-30) | | 2011-11-17 | 0000-00-00 | No | No | Current |